相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation
Ian A. Cree et al.
HISTOPATHOLOGY (2016)
PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development
Aaron R. Hansen et al.
JAMA ONCOLOGY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmune (TM) Methodology
Christopher Ung et al.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT (2016)
Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Margaret H. Veldman-Jones et al.
CANCER RESEARCH (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
Yuki Katsuya et al.
LUNG CANCER (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
Measurement of PD-L1 in melanoma: a quantitative antibody comparison
Joel C Sunshine et al.
Journal for ImmunoTherapy of Cancer (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
D. Massi et al.
ANNALS OF ONCOLOGY (2014)
A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery
Neil R. Smith et al.
JOURNAL OF PATHOLOGY (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Daniel E. Speiser et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
Richard W. Joseph et al.
CANCER IMMUNOLOGY RESEARCH (2013)
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Evan J. Lipson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
分享论文
